Status:
COMPLETED
An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum
Lead Sponsor:
Fondazione del Piemonte per l'Oncologia
Collaborating Sponsors:
Fundacao Champalimaud
Stichting Katholieke Universiteit
Conditions:
Prostate Cancer
Prostate Cancer Metastatic
Eligibility:
MALE
18-85 years
Brief Summary
In Europe, prostate cancer (PCa) is the second most frequent type of cancer in men and the third most lethal. Current clinical practices, often leading to overdiagnosis and overtreatment of indolent t...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- histological confirmed PCa or suspicion of PCa (abnormal PSA values and/or positive DRE);
- magnetic resonance imaging examination, including at least a high-resolution axial T2-weighted imaging and axila diffusion-weighted imaging (dynamic contrast-enhanced imaging is recommended, but not mandatory);
- age ≥ 18 years at the time of diagnosis
- signed written informed consent form (only for prospective enrollement).
Exclusion
Key Trial Info
Start Date :
February 24 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2025
Estimated Enrollment :
14000 Patients enrolled
Trial Details
Trial ID
NCT05384002
Start Date
February 24 2021
End Date
March 31 2025
Last Update
April 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione del Piemonte per l'Oncologia
Candiolo, Italy, Italy, 10060